Grup Bàsic i Clínic d'Immunologia i Endocrinologia
2014 SGR 394
![Foto de Grup Bàsic i Clínic d'Immunologia i Endocrinologia](/img/grupo.png)
![Foto de AstraZeneca (United Kingdom)](/img/noimage_org.png)
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublikationen in Zusammenarbeit mit Forschern von AstraZeneca (United Kingdom) (4)
2022
-
Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
Diabetes Therapy, Vol. 13, Núm. 7, pp. 1281-1298
-
Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications
Diabetes Therapy, Vol. 13, Núm. 5, pp. 873-888
2020
-
Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes
Circulation, Vol. 141, Núm. 17, pp. 1360-1370
2017
-
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
New England Journal of Medicine, Vol. 377, Núm. 13, pp. 1228-1239